Digital Newsroom

Press Releases

Welcome to the DermTech newsroom. Here you’ll find up-to-date information about the company, including our latest press releases, media coverage, and our physician blog.

DermTech’s Test Included in Expert Panel’s Clinical Management Recommendations for Cutaneous Melanoma

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its inclusion in Clinical Management Recommendations, “Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Process Assessment” published in the September issue of SKIN.

read more

DermTech Further Expands Patent Portfolio

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the issuance of patent, US 10,407,729, further expanding the company’s intellectual property and leadership position.

read more

DermTech Announces Appointment of Kevin Sun as Chief Financial Officer

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “company”), a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that Kevin Sun has been appointed as Chief Financial Officer, Treasurer and Secretary. Mr. Sun will serve on the executive leadership team and lead DermTech’s finance, investor relations, human resources and information technology functions.

read more

DermTech Announces Successful Closing of Business Combination with Constellation Alpha Capital Corp.

Combined Company Will Trade on the Nasdaq Capital Market under “DMTK” | DermTech, Inc. (“DermTech”), a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it has completed its previously announced business combination with Constellation Alpha Capital Corp. (“Constellation”), a publicly traded special purpose acquisition company prior to the business combination.

read more

Constellation Alpha Capital Corp. to Merge with DermTech, Inc., a leading innovator of genomics for dermatology and non-invasive skin cancer diagnosis

Constellation Alpha Capital Corp. (NASDAQ: CNAC) (“Constellation”), a special purpose acquisition company, announced that it has executed a definitive agreement to merge with DermTech, Inc. (“DermTech”), a molecular genomics company, with an initial focus on skin cancer, that develops and markets novel non-invasive diagnostic tests.

read more